title: [Treatment of meningococcal purpura fulminans].
abstract: In France, the incidence of meningococcal infections is increasing. The most severe presentation, called purpura fulminans, has a death rate of 20-25%; 5 to 20% of the survivors need skin grafts and/or amputations. Diagnosis of invasive meningococcal infection is very difficult when purpura and "toxic" appearance are absent: one should take into account parents' impression of their ill child. This diagnosis must be evoked in any child presenting with febrile purpura (like in the United Kingdom, parents should be encouraged to use the "tumbler test" to identify a vasculitic rash); a fulminant form is to be suspected in the presence of only one ecchymosis and signs of infection, remembering that recognition of shock is difficult in children. Recently, the Health Authority has recommended to administer a third generation cephalosporin promptly (before biological investigations) for any child with signs of infection and a necrotic or ecchymotic purpura (> 3 mm of diameter), and then to refer the patient to the hospital. By grouping the patients from 7 studies, it can be observed that preadmission antibiotic administration has a protective effect on mortality (odds ratio: 0.36; 95% confidence interval: 0.23-0.56); a negative effect was observed in only one of these series. Children with purpura fulminans should be referred to a paediatric intensive care unit. Management includes antibiotics, steroids, fluid resuscitation and catecholamines (be aware of hypoglycaemia, particularly in infants, and hypocalcaemia). Treatment of cutaneous necrosis and distal ischemia is difficult and still controversial: antithrombin, protein C, tissue plasminogen activator and vasodilator infusion have no proven efficacy. Cases must be rapidly notified to the Public Health Service who will institute chemoprophylaxis for close contacts. Given the predominance of serogroup B in France, we hope that an efficient vaccine will soon become available.
authors.affiliation: Service de réanimation pédiatrique, Hôpital Jeanne-de-Flandre, 2, avenue Oscar-Lambret, 59037 Lille, France. fleclerc@chru.lille.fr
authors.forename: F
authors.initials: F
authors.lastname: Leclerc
authors.forename: O
authors.initials: O
authors.lastname: Noizet
authors.forename: A
authors.initials: A
authors.lastname: Dorkenoo
authors.forename: R
authors.initials: R
authors.lastname: Cremer
authors.forename: S
authors.initials: S
authors.lastname: Leteurtre
authors.forename: A
authors.initials: A
authors.lastname: Sadik
authors.forename: C
authors.initials: C
authors.lastname: Fourier
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003937:Diagnosis, Differential; D006801:Humans; D011695:IgA Vasculitis / Q000175:diagnosis / Q000188:drug therapy*; D007223:Infant; D007231:Infant, Newborn; D015278:Intensive Care Units, Pediatric; D008589:Meningococcal Infections / Q000175:diagnosis / Q000188:drug therapy*; D011379:Prognosis; D012769:Shock / Q000209:etiology
chemical_list: D000900:Anti-Bacterial Agents